Latest News

ECTRIMS/EAN publish new MS treatment guidelines

January 30, 2018

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have published new guidelines on the use of disease-modifying drugs (DMDs) for multiple sclerosis (Montalban et al. Mult Scler 2018; epublished January 1, 2018; free full text at http://journals.sagepub.com/doi/pdf/10.1177/1352458517751049). The groups identified 10 key questions, and issued a series of recommendations based on the level of evidence.

The following is a summary of the groups’ recommendations. Read More

2017 U.S. drug approvals in neurology and psychiatry

January 19, 2018

The U.S. Food and Drug Administration approved 46 new therapies in 2017, up from only 22 the year before. The following is a list of the new medications for neurology and psychiatry. Read More

Long-term efficacy, safety of DMTs in MS

December 20, 2017

SPECIAL REPORT

7^TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017

Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab Read More

Vortioxetine: Improved work productivity in adults with major depression

December 13, 2017

SPECIAL REPORT

Comment by Dr. Pratap Chokka, Edmonton, Alberta

Antidepressant therapies have traditionally been evaluated for their effect on symptoms of depression and anxiety. However, symptomatic improvements may not result in functional gains in areas such as work performance and productivity, activities of daily living and quality of life. In the latest iteration of the Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder (MDD), functional recovery was recognized as a priority in the treatment of MDD in both the acute and maintenance phases of the disease (Lam et al. Ann Clin Psychiatry 2015;27:142-149). The group concluded that there was a need for evidence-based interventions that demonstrated an improvement in patient functioning. Read More